{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:40:38Z","timestamp":1793040038770,"version":"4.5.0"},"reference-count":54,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006012","name":"Christian Doppler Forschungsgesellschaft","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100006012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,7,30]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vesicular stomatitis virus (VSV) pseudotyped with the glycoprotein (GP) of the lymphocytic choriomeningitis virus (VSV-GP) represents a potent oncolytic virus (OV). Oncolytic virotherapy is an emerging anticancer approach that uses viruses to eliminate cancer cells by direct cell lysis and induction of an antitumor immune response. Immunomodulatory cargos expressed by OVs hold the potential to further enhance this antitumor immune response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      To evaluate interleukin-12 (IL-12) as an immunomodulatory cargo encoded by VSV-GP, we used a subcutaneous tumor model by mixing type I interferon (IFN) competent murine lung epithelial cells (TC-1), which are largely resistant to VSV-GP in vivo, with VSV-GP permissive IFN-\u03b1 receptor knockout TC-1 cells (TC-1\n                      <jats:italic>\n                        ifnar1\n                        <jats:sup>\u2212\/<\/jats:sup>\n                      <\/jats:italic>\n                      <jats:sup>\u2212<\/jats:sup>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This mixed model supports prolonged viral replication and subsequent IL-12 production. Oncolytic virotherapy with VSV-GP and VSV-GP-IL12 of parental TC-1 tumors did not lead to tumor control, whereas virus treatment in the TC-1\/TC-1\n                      <jats:italic>\n                        ifnar1\n                        <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      <\/jats:italic>\n                      mixed tumors showed prolonged survival. Furthermore, VSV-GP-IL12 was even more effective than VSV-GP treatment. Analysis of CD8+ T\u2009cell responses revealed phenotypic differences of activated CD8+ T cells between VSV-GP and VSV-GP-IL-12 treatment, whereby VSV-GP-IL12-induced CD8+T cells displayed a phenotype described for long-lived effector cells (LLEC). Depletion experiments indicated that CD8+ T cells, and not NK cells, were responsible for the improved efficacy observed with VSV-GP-IL12 treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Taken together, we have demonstrated that oncolytic virotherapy using VSV-GP encoding IL-12 induces CD8+ T\u2009cell responses characterized by an LLEC phenotype, a cell population that is likely a crucial component of antitumor immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-010675","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:40:30Z","timestamp":1755668430000},"page":"e010675","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype"],"prefix":"10.1136","volume":"13","author":[{"given":"Jasmin","family":"Hatami","sequence":"first","affiliation":[{"name":"Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Das","sequence":"additional","affiliation":[{"name":"ViraTherapeutics GmbH, Rum, Tyrol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Wolf","sequence":"additional","affiliation":[{"name":"Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Aufschnaiter","sequence":"additional","affiliation":[{"name":"Christian Doppler Laboratory for Viral Immunotherapy, Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria"},{"name":"Department of Internal Medicine V, Tyrolean Cancer Research Center, Medical University of Innsbruck, Innsbruck, Tyrol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Kimpel","sequence":"additional","affiliation":[{"name":"Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Nolden","sequence":"additional","affiliation":[{"name":"ViraTherapeutics GmbH, Rum, Tyrol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesa-Marie","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Christian Doppler Laboratory for Viral Immunotherapy, Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"M\u00fcllauer","sequence":"additional","affiliation":[{"name":"Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Podgorschek","sequence":"additional","affiliation":[{"name":"ViraTherapeutics GmbH, Rum, Tyrol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Schwaiger","sequence":"additional","affiliation":[{"name":"ViraTherapeutics GmbH, Rum, Tyrol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Spiesschaert","sequence":"additional","affiliation":[{"name":"ViraTherapeutics GmbH, Rum, Tyrol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Wollmann","sequence":"additional","affiliation":[{"name":"Christian Doppler Laboratory for Viral Immunotherapy, Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria"},{"name":"Department of Internal Medicine V, Tyrolean Cancer Research Center, Medical University of Innsbruck, Innsbruck, Tyrol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Elbers","sequence":"additional","affiliation":[{"name":"ViraTherapeutics GmbH, Rum, Tyrol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"von Laer","sequence":"additional","affiliation":[{"name":"Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3826-5800","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"B\u00e1nki","sequence":"additional","affiliation":[{"name":"Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"2025081922401623000_13.8.e010675.1","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"JCO"},{"key":"2025081922401623000_13.8.e010675.2","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2217\/fon-2022-0439","article-title":"Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors","volume":"18","author":"Porosnicu","year":"2022","journal-title":"Future Oncol"},{"key":"2025081922401623000_13.8.e010675.3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41416-019-0574-7","article-title":"The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer","volume":"121","author":"Schreiber","year":"2019","journal-title":"Br J Cancer"},{"key":"2025081922401623000_13.8.e010675.4","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25506-6","article-title":"A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity","volume":"12","author":"Das","year":"2021","journal-title":"Nat Commun"},{"key":"2025081922401623000_13.8.e010675.5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3306"},{"key":"2025081922401623000_13.8.e010675.6","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/ijc.31556","article-title":"Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer","volume":"143","author":"Urbiola","year":"2018","journal-title":"Int J Cancer"},{"key":"2025081922401623000_13.8.e010675.7","doi-asserted-by":"publisher","DOI":"10.1038\/77558"},{"key":"2025081922401623000_13.8.e010675.8","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.21"},{"key":"2025081922401623000_13.8.e010675.9","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.297"},{"key":"2025081922401623000_13.8.e010675.10","doi-asserted-by":"crossref","DOI":"10.3390\/v10030108","article-title":"The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma","volume":"10","author":"Kimpel","year":"2018","journal-title":"Viruses"},{"key":"2025081922401623000_13.8.e010675.11","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3770"},{"key":"2025081922401623000_13.8.e010675.12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.1.221"},{"key":"2025081922401623000_13.8.e010675.13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.1.147"},{"key":"2025081922401623000_13.8.e010675.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0472"},{"key":"2025081922401623000_13.8.e010675.15","doi-asserted-by":"publisher","DOI":"10.1038\/35074122"},{"key":"2025081922401623000_13.8.e010675.16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.14.1049"},{"key":"2025081922401623000_13.8.e010675.17","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1947"},{"key":"2025081922401623000_13.8.e010675.18","first-page":"1183","article-title":"Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma","volume":"4","author":"Motzer","year":"1998","journal-title":"Clin Cancer Res"},{"key":"2025081922401623000_13.8.e010675.19","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","article-title":"Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent","volume":"8","author":"Wang","year":"2017","journal-title":"Nat Commun"},{"key":"2025081922401623000_13.8.e010675.20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.168224","article-title":"Intratumoral aluminum hydroxide\u2013anchored IL-12 drives potent antitumor activity by remodeling the tumor microenvironment","volume":"8","author":"Battula","year":"2023","journal-title":"JCI Insight"},{"key":"2025081922401623000_13.8.e010675.21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901512"},{"key":"2025081922401623000_13.8.e010675.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.05.009"},{"key":"2025081922401623000_13.8.e010675.23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2008571117"},{"key":"2025081922401623000_13.8.e010675.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009996","article-title":"Heparan sulfate proteoglycans serve as alternative receptors for low affinity LCMV variants","volume":"17","author":"Volland","year":"2021","journal-title":"PLoS Pathog"},{"key":"2025081922401623000_13.8.e010675.25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03276-13"},{"key":"2025081922401623000_13.8.e010675.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2006.02.006"},{"key":"2025081922401623000_13.8.e010675.27","doi-asserted-by":"publisher","DOI":"10.1007\/BF01863914"},{"key":"2025081922401623000_13.8.e010675.28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300193"},{"key":"2025081922401623000_13.8.e010675.29","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27404"},{"key":"2025081922401623000_13.8.e010675.30","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202960"},{"key":"2025081922401623000_13.8.e010675.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.015"},{"key":"2025081922401623000_13.8.e010675.32","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425770"},{"key":"2025081922401623000_13.8.e010675.33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.7.1241"},{"key":"2025081922401623000_13.8.e010675.34","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32325"},{"key":"2025081922401623000_13.8.e010675.35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.omto.2023.02.002","article-title":"Reprogramming the tumor microenvironment leverages CD8+ T cell responses to a shared tumor\/self antigen in ovarian cancer","volume":"28","author":"Mistarz","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"2025081922401623000_13.8.e010675.36","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0590"},{"key":"2025081922401623000_13.8.e010675.37","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.vaccine.2003.07.003","article-title":"Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes","volume":"22","author":"Cassetti","year":"2004","journal-title":"Vaccine (Auckl)"},{"key":"2025081922401623000_13.8.e010675.38","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/149185","article-title":"Chronic inflammation and cytokines in the tumor microenvironment","volume":"2014","author":"Landskron","year":"2014","journal-title":"J Immunol Res"},{"key":"2025081922401623000_13.8.e010675.39","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41434-020-00205-x","article-title":"Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1","volume":"28","author":"Kim","year":"2021","journal-title":"Gene Ther"},{"key":"2025081922401623000_13.8.e010675.40","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2011.125"},{"key":"2025081922401623000_13.8.e010675.41","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020400","article-title":"Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy","volume":"9","author":"Nguyen","year":"2020","journal-title":"Cells"},{"key":"2025081922401623000_13.8.e010675.42","doi-asserted-by":"crossref","first-page":"11548","DOI":"10.3390\/cimb46100686","article-title":"Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy","volume":"46","author":"Dong","year":"2024","journal-title":"CIMB"},{"key":"2025081922401623000_13.8.e010675.43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25010211","article-title":"Development of Recombinant Oncolytic rVSV-mIL12-mGMCSF for Cancer Immunotherapy","volume":"25","author":"Ryapolova","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025081922401623000_13.8.e010675.44","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlg.0000246194.66295.d8"},{"key":"2025081922401623000_13.8.e010675.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01233-9"},{"key":"2025081922401623000_13.8.e010675.46","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.09017","article-title":"An extrafollicular pathway for the generation of effector CD8(+) T cells driven by the proinflammatory cytokine, IL-12","volume":"4","author":"Shah","year":"2015","journal-title":"Elife"},{"key":"2025081922401623000_13.8.e010675.47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3944"},{"key":"2025081922401623000_13.8.e010675.48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0304"},{"key":"2025081922401623000_13.8.e010675.49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2085"},{"key":"2025081922401623000_13.8.e010675.50","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.vaccine.2003.09.023","article-title":"Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA)","volume":"22","author":"Chakrabarti","year":"2004","journal-title":"Vaccine (Auckl)"},{"key":"2025081922401623000_13.8.e010675.51","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9306","article-title":"Functional classification of memory CD8(+) T cells by CX3CR1 expression","volume":"6","author":"B\u00f6ttcher","year":"2015","journal-title":"Nat Commun"},{"key":"2025081922401623000_13.8.e010675.52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02692","article-title":"Defining Memory CD8 T Cell","volume":"9","author":"Martin","year":"2018","journal-title":"Front Immunol"},{"key":"2025081922401623000_13.8.e010675.53","doi-asserted-by":"crossref","DOI":"10.1038\/srep12264","article-title":"Early Effector CD8 T Cells Display Plasticity in Populating the Short-Lived Effector and Memory-Precursor Pools Following Bacterial or Viral Infection","volume":"5","author":"Plumlee","year":"2015","journal-title":"Sci Rep"},{"key":"2025081922401623000_13.8.e010675.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.07.010"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:40:33Z","timestamp":1755668433000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,19]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/jitc-2024-010675"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010675","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}